PELICAN THERAPEUTICS, INC.
TL1A-Ig fusion protein therapeutic to expand regulatory T cells and prevent graft-versus-host disease after stem cell transplantation
- Sector
- Biotech
- Headquarters
- San Antonio, TX
- Latest Form D
- $250K, Aug 2015
- Total capital
- $635K
- Federal grants
- $225K
- 1 award · 2020
- Rank in peer group#311 of 392
- Private capital raised
- $410K
- 2 Form D · last Aug 2015
- 134 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 4
- 15 pending · first 2018
- Rank in peer group#35 of 392
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase I · Application of TNFRSF25 agonists for prophylaxis and treatment of graft versus host disease$225K
- Private capital raisedForm D · SEC · 2nd filing$250K
- Private capital raisedForm D · SEC · 1st filing$160K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 392 peers
Line = medianBiotech · Molecule
- Federal grantsBelow median
- Granted patents#35 · top 9%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Taylor H. SchreiberResearcherDirectorLinked by 4 patents
- Edward B. SmithDirectorNamed in SEC Form D filings
- Jeffrey WolfDirectorNamed in SEC Form D filings
- Josiah HornblowerExecutive Officer, DirectorNamed in SEC Form D filings
- Jules MusingDirectorNamed in SEC Form D filings
- Nico M. PronkDirectorNamed in SEC Form D filings
Show all 8 people
- Rahul JasujaDirectorNamed in SEC Form D filings
- Shawn M. TitcombDirectorNamed in SEC Form D filings
What it has protected
USPTO · 4 granted of 19- PendingMethods Of Treating Cancer Using TNFRSF25 AntibodiesUSPTOApplication 17637686
- PendingANTI-TNFRSF25 AntibodiesUSPTOApplication 16874290
- PendingHuman TNFRSF25 AntibodyUSPTOApplication 16874280
Show all 19 patent records
- Methods Of Treating Cancer Using TNFRSF25 AntibodiesSep 22, 2022 · Application 17637686Pending
- ANTI-TNFRSF25 AntibodiesJan 21, 2021 · Application 16874290Pending
- Human TNFRSF25 AntibodyDec 17, 2020 · Application 16874280Pending
- ANTI-TNFRSF25 AntibodiesJun 16, 2020 · US 10,683,359Granted
- Human TNFRSF25 AntibodyJun 16, 2020 · US 10,683,358Granted
- ANTI-TNFRSF25 AntibodiesJun 26, 2018 · US 10,005,843Granted
- Human TNFRSF25 AntibodyMay 29, 2018 · US 9,982,057Granted
- ANTI-TNFRSF25 AntibodiesApplication PCTUS2017036817Pending
- ANTI-TNFRSF25 AntibodiesApplication 62348009Pending
- Human TNFRSF25 AntibodyApplication PCTUS2015061082Pending
- Human TNFRSF25 antibodyApplication 62134740Pending
- Treatment Of Autoimmune Inflammatory Diseases With TNFRSF25-BINDING AgentsApplication PCTUS2022029622Pending
- Human TNFRSF25 antibodyApplication 62080694Pending
- Treatment Of Autoimmune Inflammatory Diseases With TNFRSF25-BINDING AgentsApplication 63323252Pending
- Treatment Of Autoimmune Inflammatory Diseases With TNFRSF25-BINDING AgentsApplication 63189774Pending
- Methods Of Treating Cancer Using TNFRSF25 AntibodiesApplication PCTUS2020048195Pending
- Methods Of Treating Cancer Using TNFRSF25 AntibodiesApplication 62932028Pending
- Methods Of Treating Cancer Using TNFRSF25 AntibodiesApplication 62903363Pending
- Methods Of Treating Cancer Using TNFRSF25 AntibodiesApplication 62894095Pending
Related companies, and why
- Oisin Biotechnologies, Inc.Similar federal contract value in Biotech · null in contracts
- Inozyme PharmaSimilar federal contract value in Biotech · null in contracts
- Encepheal Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Acomhal Research, Inc.Similar federal contract value in Biotech · null in contracts
- ZUCHEM INC.Similar federal contract value in Biotech · null in contracts
- Deepcell, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .